Assessment of FDA and EMA approved systemic oncology therapies and clinically meaningful improvements in quality of life

JAMA Network Open

11 February 2021 - Are oncology therapies recently approved by the US FDA and the EMA associated with clinically meaningful improvements in quality of life?

In this systematic review of approved oncology therapies, 40% of FDA approved and 58% of EMA approved indications had published quality of life evidence. 

However, only 6% and 11% of FDA and EMA approved indications, respectively, had clinically meaningful improvements in quality of life beyond minimal clinically important differences.

Read JAMA Network Open article

Michael Wonder

Posted by:

Michael Wonder